Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Diagnosis of primary brain tumor or brain metastases, meeting 1 of the following criteria:
• •* No radiographic evidence of disease
• •* Stable disease, defined as no tumor progression within the past 3 months
• •Previously treated with 1 course of localized or whole brain radiotherapy of at least 3,000 cGy at least 6 months before study registration
• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Performance status
• •Karnofsky 70-100%
• •Life expectancy
• •At least 30 weeks
• •Hematopoietic
• •Not specified
• •Hepatic
• •Not specified
• •Renal
• •Not specified
• •Other
• •Not pregnant or nursing
• •Negative pregnancy test
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •Not specified
• •Chemotherapy
• •No concurrent chemotherapy
• •Endocrine therapy
• •Concurrent steroid therapy allowed if on stable or decreasing dose
• •Radiotherapy
• •See Disease Characteristics
• •No concurrent cranial radiotherapy
• •Surgery
• •No concurrent surgery
• •Other
• •More than 3 months since prior donepezil or EGb761
• •No concurrent donepezil (group 2 only)
• •No concurrent EGb761 (group 1 only) (closed to accrual 10/09/03)
• •No concurrent anticoagulants (e.g., aspirin, dipyridamole, heparin, warfarin, or enoxaparin) (group 2 only)
• •No concurrent monoamine oxidase inhibitors (e.g., phenelzine or tranylcypromine)
• •No other concurrent therapy